CAS: 102-47-6; 1,2-Dichloro-4-(Chloromethyl)Benzene

上下游产品

CAS号1805-32-9 3,4-二氯苄醇 | CAS号6287-38-3 3,4-二氯苯甲醛 | CAS号50-00-0 甲醛 | CAS号95-50-1 邻二氯苯 | CAS号95-75-0 3,4-二氯甲苯 | CAS号100-44-7 氯化苄 | CAS号107-30-2 氯甲基甲醚 | CAS号55513-17-2 1-(3,4-二氯苄基)哌嗪 | CAS号56442-18-3 4-[(3,4-二氯苄基)氧基]苯羧酸 | CAS号3218-49-3 3,4-二氯苯乙腈 | CAS号142523-67-9 3,4-二氯苄碘 | CAS号220772-52-1 1-(3,4-二氯苄基)-4-哌啶酮 | CAS号22297-13-8 (3,4-dichloroph... | CAS号22816-60-0 {氨基[(3,4-二氯苄基)硫... | CAS号36480-40-7 3,4-二氯苯甲硫醇 | CAS号2635-78-1 tributyl-[(3,4-... | CAS号85952-30-3 (3,4-二氯苯基)甲烷磺酰氯

3,4-二氯苯甲酸置于氯化亚砜,硼烷四氢呋喃络合物体系中,用 四氢呋喃 用作溶剂,化学反应 4.0H,反应生成3,4-二氯氯苄
参考文献:N-(取代磺酰基)苯甲酰胺类衍生物及其制备方法和医药用途
标题:N-(取代磺酰基)苯甲酰胺类衍生物及其制备方法和医药用途
摘要:本发明涉及n‑(取代磺酰基)苯甲酰胺类衍生物及其制备方法和医药用途.具体而言,本发明涉及一种通式(I)所示的n‑(取代磺酰基)苯甲酰胺类衍生物,其制备方法及其可药用的盐,以及它们作为治疗剂,特别是作为nav1.7抑制剂的用途,其中通式(I)中的各取代基的定义与说明书中的定义相同.

专利信息

专利号:EP-3792250-A1
优先权日:2019-09-13
标题:Synthesis of alpha-amanitin and its derivatives
发明人：SIEGERT MARY-ANN; KNITTEL CAROLINE HERTA; SÃœSSMUTH RODERICH
权利人:PURE BIOORGANICS SIA
摘要:The present invention relates to the chemical synthesis of α-amanitin and its derivatives. The present invention also relates to intermediate products of the α-amanitin synthesis.

专利号:US-7189864-B2
优先权日:1990-11-19
标 题:Method of preparing intermediates useful in synthesis of retroviral protease inhibitors
发明人：NG JOHN S; PRZYBYLA CLAIRE A; MUELLER RICHARD A; VAZQUEZ MICHAEL L; GETMAN DANIEL P
权利人:SEARLE & CO
摘要:A synthesis is described for intermediates which are readily amenable to the large scale preparation of hydroxyethylurea-based chiral HIV protease inhibitors. The method includes forming a diastereoselective epoxide from a chiral alpha amino aldehyde.

专利号:US-8034966-B1
优先权日:2008-02-20
标 题:Phenoxyisobutyric acid compounds and methods for synthesis
发明人：LALEZARI IRAJ; FABRICANT JILL
权利人:CELL VIABLE CORP
摘要:The present invention provides a process for the synthesis of substituted arylureidophenoxymethylpropionic acid and related compounds including bifunctional and tetrafunctional derivatives. The compounds are useful for inhibiting the formation of AGEs (Aminaglycation end products).

专利号:US-6022996-A
优先权日:1990-11-19
标 题 :Method for making intermediates useful in synthesis of retroviral protease inhibitors
发明人：NG JOHN S; PRZYBYLA CLAIRE A; MUELLER RICHARD A; VAZQUEZ MICHAEL L; GETMAN DANIEL P
权利人:SEARLE & CO
摘要:A synthesis is described for intermediates which are readily amenable to the large scale preparation of hydroxyethylurea-based chiral HIV protease inhibitors. The method includes forming a diastereoselective epoxide from a chiral alpha amino aldehyde.

专利号:EP-0641333-B1
优先权日:1992-05-20
标 题 :Method for making intermediates useful in synthesis of retroviral protease inhibitors
发明人：NG JOHN S; PRZYBYLA CLAIRE A; MUELLER RICHARD A; VAZQUEZ MICHAEL L; GETMAN DANIEL P
权利人:SEARLE & CO; MONSANTO CO
摘要:A synthesis is described for intermediates which are readily amenable to the large scale preparation of hydroxyethylurea-based chiral HIV protease inhibitors. The method includes forming a diastereoselective epoxide compound of formula (I) from a chiral alpha amino aldehyde and halomethyllithium as an organometallic methylene-adding reagent. In formula (I) R<1> is selected from alkyl, aryl, cycloalkyl, cycloalkylalkyl and arylalkyl, which are optionally substituted with a group selected from alkyl, halogen, NO2, OR<9> or SR<9>, where R<9> represents hydrogen or alkyl; and P<1> and P<2> independently are selected from amine protecting groups, including but not limited to, arylalkyl, substituted arylalkyl, cycloalkenylalkyl and substituted cycloalkenylalkyl, allyl, substituted allyl, acyl, alkoxycarbonyl, aralkoxycarbonyl and silyl.

专利号:EP-0855388-B1
优先权日:1993-11-23
标 题 :Method for making intermediates useful in synthesis of retroviral protease inhibitors
发明人：NG JOHN S; PRZYBYLA CLAIRE A; MUELLER RICHARD A; VAZQUEZ MICHAEL L; GETMAN DANIEL P; FRESKOS JOHN J; DECRESCENZO GARY A; BERTENSHAW DEBORAH E; HEINTZ ROBERT M; ZHANG SUHONG; LIU CHIN; LANEMAN SCOTT A
权利人:SEARLE & CO
摘要:A synthesis is described for intermediates which are readily amenable to the large scale preparation of hydroxyethylurea-based chiral HIV protease inhibitors. The method includes forming a cyanohydrin from a chiral alpha amino aldehyde.